Delivery Order SPE2DR25D2100-SPE2DR26FA0FX
- Not listed
- The Defense Logistics Agency awarded a $12,047.87 delivery order to AmerisourceBergen Drug Corp for the supply of Durolane 60 mg/3 ml syringes on January 12, 2026, with an ultimate completion date of January 13, 2026. This is a firm fixed-price contract with no set-aside designation, meaning the award was made through full and open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 29, 2025, for the supply of Durolane 60 mg/3 mL syringes with a ceiling value of $8,957.53. This is a firm fixed price delivery order with no set-aside designation, representing a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of December 30, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a $1,679.80 delivery order to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Durolane 60 mg/3 ml syringes. This competitively awarded, firm fixed-price delivery order is expected to be completed by December 4, 2025, with fulfillment occurring at the vendor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a...
- The Defense Logistics Agency awarded a delivery order valued at $5,495.41 to AmerisourceBergen Drug Corp for the supply of Durolane 60 mg/3 mL syringes on December 11, 2025, with completion targeted for December 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's significantly...
- The Defense Logistics Agency awarded a delivery order valued at $1,593.95 to AmerisourceBergen Drug Corp for the supply of Durolane 60 mg/3 mL syringes on a firm fixed price basis. The contract was competitively awarded without set-aside designation and is scheduled for completion by April 24, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $12,347.52 by the Defense Logistics Agency on August 1, 2025, for Durolane 60 mg/3 mL syringes. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award status. Performance is scheduled for completion by August 4, 2025, with work to be performed at the contractor's Conshohocken facility. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of Durolane 60 mg/3 ml syringes with a ceiling value of $12.7K under firm fixed pricing. This is a non-set-aside, competitively awarded contract with an ultimate completion date of December 5, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Durolane 60 mg/3 mL syringes valued at $7,568.71, with an ultimate completion date of November 13, 2025. This contract was awarded on a firm fixed-price basis without set-aside designation, indicating competitive procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $4,612.80 to Amerisourcebergen Drug Corp for the supply of Durolane 60 mg/3 mL syringes (3 mL quantity) on January 27, 2026, with an ultimate completion date of January 28, 2026. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is located in Conshohocken, Pennsylvania, where Amerisourcebergen Drug Corp maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $10,859.54 to AmerisourceBergen Drug Corp for Durolane 60 mg/3 mL syringes (3 mL) on September 16, 2025, with an ultimate completion date of September 17, 2025. This non-competitive, firm fixed-price delivery order was placed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at...
- SPE2DR25D2100Indefinite Delivery Contract
- SPE2DR25D2100-SPE2DR26FA0FXDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of Durolane 60 mg/3 ml syringes with a contract value of $2,290.11 and an ultimate completion date of November 25, 2025. This non-competitive delivery order utilizes firm fixed pricing and is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion prime vendor agreement designated SPE2DX and running through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a leading pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, supplying a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. This delivery order for Durolane, a hyaluronic acid injection used for osteoarthritis treatment, exemplifies the company's role in fulfilling specialized medical supply requirements for the Defense Health Agency and other federal healthcare customers. The company's qualification for multiple federal contracts reflects its demonstrated capability to meet federal procurement standards through open competition and its established position within the DLA's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 11/23/25 |